{"id":1124,"date":"2025-09-13T06:00:40","date_gmt":"2025-09-13T06:00:40","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=1124"},"modified":"2026-03-15T11:05:56","modified_gmt":"2026-03-15T11:05:56","slug":"how-we-use-ultrasound-to-support-clinical-decisions-on-fluid-administration-in-critical-ill-patients","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/09\/13\/how-we-use-ultrasound-to-support-clinical-decisions-on-fluid-administration-in-critical-ill-patients\/","title":{"rendered":"How we use ultrasound to support clinical decisions on fluid administration in critical ill patients"},"content":{"rendered":"

\ud83e\ude7a How Ultrasound Guides Fluid Administration in Critical Illness<\/p>\n

\n

Abstract:<\/strong><\/p>\n<\/blockquote>\n

Intravenous fluids are among the most frequently used therapies in critical care but must be considered drugs, carrying both benefits and risks. Critical care ultrasound (CCUS)\u2014through echocardiography (CCE), lung ultrasound (LUS), and venous excess ultrasound (VExUS)\u2014offers a structured way to assess the risks and benefits of fluid administration. This article outlines a stepwise framework for integrating ultrasound into bedside decision-making during the optimization and stabilization phases of critical illness.<\/p>\n

\n

Key Insights:<\/strong><\/p>\n<\/blockquote>\n

    \n
  1. \n

    Fluids should be considered only when tissue hypoperfusion is evident, with CCUS serving as the main tool to balance risks and benefits .<\/p>\n<\/li>\n

  2. \n

    CCE helps identify overt hypovolemia by evaluating LV end-diastolic area (<10 cm\u00b2) and signs like \u201ckissing walls\u201d; a small IVC diameter (\u226410 mm) supports the diagnosis .<\/p>\n<\/li>\n

  3. \n

    Advanced CCE may also reveal left ventricular outflow tract obstruction in hypovolemic patients, requiring immediate fluids to prevent collapse .<\/p>\n<\/li>\n

  4. \n

    In the absence of overt hypovolemia, CCE screens for cardiac conditions such as RV dilation (RV\/LV ratio >0.6), severe valve disease, or elevated LV filling pressures, which increase fluid risk .<\/p>\n<\/li>\n

  5. \n

    Doppler parameters like E\/e\u2032 >8 or e\u2032 \u22648 cm\/s help identify elevated LV filling pressures; an E\/A ratio >1.8 confirms this with high specificity .<\/p>\n<\/li>\n

  6. \n

    LUS evaluates pulmonary congestion: an A-profile (<3 B-lines) suggests low risk for edema, whereas a bilateral B-profile (\u22653 B-lines) indicates increased risk, especially if heterogeneous .<\/p>\n<\/li>\n

  7. \n

    Pleural abnormalities and large bilateral effusions further raise concern for fluid-induced pulmonary edema .<\/p>\n<\/li>\n

  8. \n

    VExUS detects systemic venous congestion, with IVC \u226520 mm plus abnormal hepatic, portal, or renal venous flow patterns signaling high congestion risk .<\/p>\n<\/li>\n

  9. \n

    Functional testing with LVOT-VTI changes during passive leg raise or inspiratory\/expiratory occlusion predicts fluid responsiveness and bolus efficacy .<\/p>\n<\/li>\n

  10. \n

    CCUS integration allows fluid decisions tailored to individual physiology rather than fixed thresholds, supporting safer and more effective hemodynamic management .<\/p>\n<\/li>\n<\/ol>\n

    \n
    \n
    \n
    \n
    Minimize image<\/div>\n
    Edit image<\/div>\n
    Delete image<\/div>\n<\/div>\n<\/div>\n

    \"\"<\/p>\n<\/div>